Stocksrunner
Posted - 11 hours ago
$BMY Bristol-Myers Squibb is moving past a key level of resistance at $54.36. The RSI shows it's gaining strength, and with 45M+ volume, more buyers are getting in. This could mean more gains ahead! https://stocksrunner.com/symbol/BMY
Yloo
Posted - 1 day ago
$NMRA 0.85m shares dumped at the close. Leaking?
Not necessarily. This dumping didn't cause a price collapse. So it's likely rebalancing the position on the quadruple option expiration day. This can also be observed in all major stocks NVDA SMCI $TSLA $LLY, $BMY But it doesn't mean Monday won't be a PR day for ph3 readout. WO.
My thesis: high success rate in PH3, much higher than prostate cancer vaccine $CADL, but CADL succeeded in its ph3 readout.
And NMRA is so out of the mainstream that it may surprise the street on the positive side but with subdued negative impact. No one is buying and holding it, so not many people could dump it. we should see.
@Doozio Take a look at this
DividendPower
Posted - 1 day ago
Recent Dividend Increases - Updated 12/20/24 https://www.dividendpower.org/dividend-increases/ $ANDE $ERIE $THFF $MA $BMY
Deenjdeenj
Posted - 1 day ago
$BMY Yessirrr!! 🚀🚀
Paco_the_Dirty_Gringo
Posted - 1 day ago
$PTIX’s work in CNS treatments is rapidly progressing. If you’ve seen $BMY’s success in oncology, $PTIX could be your next biotech opportunity with huge growth potential in mental health.
ThisIsBiotech
Posted - 1 day ago
$BMY Is Cereno Scientific the Next Big Deal? CS1 vs. Sotatercept Sotatercept (now Winrevair), Acceleron’s PAH candidate, drove Merck’s $11.5 billion acquisition, with analysts estimating it accounted for 70–80% of the deal value. BMS, a major shareholder in Acceleron, reportedly considered raising its bid but ultimately lost to Merck. Now, Cereno's CS1 is emerging as a best-in-class, disease-modifying treatment with the potential to surpass Sotatercept. Early data highlights CS1’s novel mechanism, strong efficacy, and favorable safety profile. Compassionate use approvals and topline results further validate its promise. World-renowned Dr.Deepak Bhatt, who serves on BMS’s board, is also a member of Cereno's Scientific Advisory Board, providing a unique connection between the two companies. With the PAH market valued at over $7B and a CAGR exceeding 5%, the opportunity is massive. Having missed Winrevair, BMS could now see CS1 as its next blockbuster target in PAH treatment.
JuggernautRaider
Posted - 2 days ago
$PPBT agreed @Smittysixty - PPBT is insanely undervalued like $JFBR and $TNXP . I want to read up more on their agreement with $BMY on CM24 given it is administered with Opdivo & Standard/of-care chem in 2L+ pancreatic cancer.
I wonder if $BMY has a poison pill to acquire them or partner. If so, it would explain why they have not started hiring American employees to commercialize here as BMS may just buy them out (CM24 is a divested BMS asset If I recall correctly). @PurpleBiotech & @purplebison : check out this @Beautiful @biotech @Pipelines4Life :
Deenjdeenj
Posted - 2 days ago
$BMY Flying Friday tomorrow 💸💸
lcc007
Posted - 2 days ago
$BMY Latest SMA AI Forecast
lcc007
Posted - 2 days ago
@Wigglyick $BMY here ya go!
SniperPro
Posted - 2 days ago
$LXRX THE MAN behind SOTA research... check this out: Dr Deepak L. Bhatt Underscores Sotagliflozin Benefits Seen in SOLOIST, SCORED https://www.ajmc.com/view/dr-deepak-l-bhatt-underscores-sotagliflozin-benefits-seen-in-soloist-scored He's currently a board director at $BMY https://www.bms.com/about-us/leadership/board-of-directors/deepak-l-bhatt.html Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2030183 Authors: Deepak L. Bhatt, M.D., M.P.H. , Michael Szarek, Ph.D., P. Gabriel Steg, M.D., Christopher P. Cannon, M.D. , Lawrence A. Leiter, M.D., Darren K. McGuire, M.D., M.H.Sc., Julia B. Lewis, M.D., +12 , for the SOLOIST-WHF Trial Investigators FDA DO THE RIGHT THING... DIABETES COMMUNITY WORLDWIDE IS EXPECTING YOUR BEST!!!
Walter100
Posted - 2 days ago
$BMY : Has a strong oncology portfolio with drugs like Opdivo (nivolumab), but their effectiveness in gastric cancer is modulated by PD-L1 expression levels (CPS). DKN-01's effectiveness regardless of PD-1/PD-L1 expression could expand their treatment options, potentially reaching a broader patient population.
GPS_OS_21_vs_SOC_5
Posted - 2 days ago
$SLS @Jackedmoney Yes - I do, and I might be Happier. The Math Stacks Up for Just Gps Being Worth $24B to Big Pharmaceutical Just for AML... That's a $6B TAM at a 4x price to Sales Ratio - smaller Pharma's have 10x Price to sales market caps. . . $10B is a 40% dNPV for just Gps w in AML. Its Use in Gps Opdivo $BMY combo in Mesothelioma 28 months of OS for Responders vs 28 weeks wSOC - Gps Keytruda $MRK 18.4 months of Os in PROC vs 16.46 for Elahere that GOT BOUGHT for 10.1B... so yes then Add 009 Value - BP knows right now based not the Safety Profile its getting fda approval, 100% CR rates for end stage, post ven relapsed R/R AML patients, a Not Yet Met OS, Already 3X + longer than historical norms. - $ABBV $RHHBY $BMY - Ven and Aza owners all could easily rationalize a multibillion dollar 009 buy, just for the 30,000 ASXL1+ AML/MDS patients dxd each year.
PFElinepfrenzy1990
Posted - 2 days ago
$PFE $BMY $AZN $LLY - Well, I suppose healthcare bad AI good 🙄 who needs healthcare when we have Blackwell chips and self-driving cars and quantum computing?
SPG565
Posted - 2 days ago
$BMY Priced for total earnings of $3.50 in 2025. What happens when they make possibly $7? 🤔
OptionSamurai
Posted - 2 days ago
$BMY appears in our Dividend Capture scan. The idea is to buy shares + sell call to enjoy premium and the dividend.
☑ The Fundamental score is 9
☑ Growth score is 9
☑ Dividend date 03-Jan-25
☑ IV Percentile is 58.7%
Covered Call 57.0, 03-Jan-25:
📈 An annualized return of 36.7%
📉 The breakeven point is 1.5%
👉 See more results & customize here: https://bit.ly/3lR1xIP
Apr4609
Posted - 2 days ago
@Walter100 Furthermore, I doubt retailers at $BMY, $MRK, $BGNE care about gastric cancer (maybe beigene) but leap is about to show that adding dkn-01 to one of their pd-1 will make the other companies obsolete unless they add other products to their pd-1
Global reach and other collaborations with $gild and $roche are also in the background
Article_AI
Posted - 2 days ago
$BMY 3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio. https://www.stck.pro/news/BMY/96530880/
ThisIsBiotech
Posted - 2 days ago
The deal grants $BMY global rights to BioArctic's preclinical antibody candidates, BAN1503 and BAN2803, aimed at treating Alzheimer's disease. The agreement includes an upfront payment of $100 million, with potential milestone payments bringing up to $1.3 billion In light of BMS's recent collaborations, attention is turning at innovative SWE Biotech. Cereno Scientific, has developed CS1, a novel treatment for PAH. PAH with a market of $ 7B anually and a CAGR of 5%. CS1 is an HDAC inhibitor that works through epigenetic modulation, aiming to reverse the pathological vascular remodeling of the small lung arteries associated with PAH. The recent positive Phase IIa trial results for CS1 demonstrated a favorable safety profile and compelling signs of clinical efficacy. CU from FDA accepted and pivotal trail is the next step. Given BMS's history of strategic acquisitions and partnerships, CS1 presents a compelling opportunity. That would give BMS with a novel therapeutic avenue in PAH.
Article_AI
Posted - 2 days ago
$BMY Got $250? 2 Healthcare Stocks to Buy and Hold Forever One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy. https://www.stck.pro/news/BMY/96519121/
Article_AI
Posted - 2 days ago
$BMY These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy? It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast amounts of capital. https://www.stck.pro/news/BMY/96516801/
DMcL
Posted - 2 days ago
$RVPH Comparison of the rollover patients efficacy from Reviva and $BMY drugs. TLDR. Reviva has better efficacy on a small subset of Rollover patients, full OLE data required for more accurate comparison.
Key takeaway: Brilaroxazine's efficacy is comparable to Cobenfy from early data.
Capitulation_0
Posted - 3 days ago
$CYTK May be better asa standalone company: RBC Capital⬆️the PT on $CYTK to $82 was $80/Outperform, says "With the potential aficamten launch trajectory top of mind for many investors, we took the time to review the launch of the closest comparable drug - BMY's Camzyos:" $BMY $BAYRY $EWTX "Our analysis suggests that the Camzyos launch was better than investor sentiment around it seems to imply, and that if aficamten meets or exceeds the Camzyos trajectory, it could be among the more successful launches among near-term approvals. Given the potential advantages aficamten may have on efficacy, as well as the convenience of the drug, we believe aficamten is likely to do better than Camzyos, and we expect a strong launch that can provide line of sight to a >$3.6B opportunity. With shares not fully appreciating the opportunity, we would be buyers. Tgt to $82 on model updates based on the recent Bayer partnership." https://x.com/Quantumup1/sta/Quantumup1/status/1846984773698281983
SPG565
Posted - 3 days ago
$PFE $BMY $C
Absolutely ridiculous selling. I'd add if you have cash or sell Puts
MF__DOOM
Posted - 3 days ago
$BMY $56 potentially breaking down $SPY $QQQ
MF__DOOM
Posted - 3 days ago
$BMY hold $56 for today
JuggernautRaider
Posted - 3 days ago
$PPBT your PPS expectations are reasonable @iambaron . @PPBT4LYFE knows: @PurpleBiotech is a WINNER!
They need to start hiring North American employees with pancreatic cancer experience from $BMY or $RVMD or even $NVCR to show they are preparing for launch. They may need a phase 3 but a 2 month OS in 2L pancreatic cancer is significant.
achr_trader
Posted - 3 days ago
$BMY
